TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2544.
Locate Jan Aushadhi KendraClinical Overview
Advanced next-generation dihydropyridine calcium channel blocker (L/T-type or L/N/T-type blocker). Provides gradual, prolonged systemic vasodilation with high vascular selectivity and minimal reflex sympathetic stimulation, protecting coronary, cerebral, and renal microvasculature. Indicated for essential hypertension, renal parenchymal hypertension, and angina pectoris.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally with water, once or twice daily after meals as prescribed. Swallow whole. Maintain consistent daily dosing.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Headache, flushing, dizziness, mild nausea, constipation, ankle swelling. Rare/Severe: Marked hypotension and hepatic dysfunction.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in cardiogenic shock. Caution in elderly patients and severe hepatic impairment. Do not discontinue abruptly.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.